A systematic review on Richter syndrome: what is the published evidence?

被引:30
作者
Molica, Stefano [1 ]
机构
[1] Azienda Osped Pugliese Ciaccio, Dept Hematol Oncol, I-88100 Catanzaro, Italy
关键词
Richter syndrome; CLL; systematic review; CHRONIC-LYMPHOCYTIC-LEUKEMIA; B-CELL LYMPHOMA; FRACTIONATED CYCLOPHOSPHAMIDE; LIPOSOMAL DAUNORUBICIN; 2ND MALIGNANCIES; RISK-FACTORS; TRANSFORMATION; FLUDARABINE; RITUXIMAB; THERAPY;
D O I
10.3109/10428190903515192
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A systematic and comprehensive search of literature was performed using MEDLINE databases from 1st January 1978 to 2nd November 2009 and hand search of references. A search performed by combining the Medical Subject Headings (MESH) terms 'Richter's syndrome' and 'chronic lymphocytic leukemia' (CLL) yielded 143 citations. Ten additional case-control studies judged relevant for the purpose of study were also included. In total, 45 case reports, 18 case series, and 9 case-control studies were identified. For the purpose of this review, only case series and case-control studies were considered. The following conclusions could be drawn from the studies analyzed in this review: (i) some biological markers (i.e. CD38 expression and genotype, absence of del13q) or clinical features (i.e. bulky lymph node involvement), although not validated in prospective trials, may be considered for close monitoring and a careful biopsy policy; (ii) PET, is not yet standardized in RS, however, it may be useful in the diagnosis and to choose the site for biopsy; (iii) when diagnosed RS should be treated with a combination of rituximab and polychemotherapy; (iii) younger patients who respond to initial therapy should be offered allogeneic SCT, if feasible. Despite the paucity of data, it is important to note that this article represents the first systematic review of the entire body of available clinical evidence useful for an appropriate management of Richter transformation.</.
引用
收藏
页码:415 / 421
页数:7
相关论文
共 32 条
[1]   CD38 gene polymorphism and chronic lymphocytic leukemia:: a role in transformation to Richter syndrome? [J].
Aydin, Semra ;
Rossi, Davide ;
Bergui, Luciana ;
D'Arena, Giovanni ;
Ferrero, Enza ;
Bonello, Lisa ;
Omede, Paola ;
Novero, Domenico ;
Morabito, Fortunato ;
Carbone, Antonino ;
Gaidano, Gianluca ;
Malavasi, Fabio ;
Deaglio, Silvia .
BLOOD, 2008, 111 (12) :5646-5653
[2]  
Bruzzi JF, 2006, J NUCL MED, V47, P1267
[3]   Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial [J].
Catovsky, D. ;
Richards, S. ;
Matutes, E. ;
Oscier, D. ;
Dyer, M. J. S. ;
FBezares, R. ;
Pettitt, A. R. ;
Hamblin, T. ;
Milligan, D. W. ;
Child, J. A. ;
Hamilton, M. S. ;
Dearden, C. E. ;
Smith, A. G. ;
Bosanquet, A. G. ;
Davis, Z. ;
Brito-Babapulle, V. ;
Else, M. ;
Wade, R. ;
Hillmen, P. .
LANCET, 2007, 370 (9583) :230-239
[4]   Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias [J].
Cheson, BD ;
Vena, DA ;
Barrett, J ;
Freidlin, B .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2454-2460
[5]   Limitations of Gallium-67 SPECT in histological transformation of chronic lymphocytic leukaemia:: an analysis of 13 patients with clinically suspected Richter's syndrome [J].
Cobo, F ;
Rosiñol, L ;
Martínez, A ;
Martín, F ;
Esteve, J ;
Gómez, M ;
Nadal, E ;
Bosch, F ;
Setoain, FJ ;
Campo, E ;
Montserrat, E .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (02) :484-487
[6]   Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoxome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome [J].
Dabaja, BS ;
O'Brien, SM ;
Kantarjian, HM ;
Cortes, JE ;
Thomas, DA ;
Albitar, M ;
Schlette, ES ;
Faderl, S ;
Sarris, A ;
Keating, MJ ;
Giles, FJ .
LEUKEMIA & LYMPHOMA, 2001, 42 (03) :329-337
[7]   Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines [J].
Hallek, Michael ;
Cheson, Bruce D. ;
Catovsky, Daniel ;
Caligaris-Cappio, Federico ;
Dighiero, Guillaume ;
Doehner, Hartmut ;
Hillmen, Peter ;
Keating, Michael J. ;
Montserrat, Emili ;
Rai, Kanti R. ;
Kipps, Thomas J. .
BLOOD, 2008, 111 (12) :5446-5456
[8]   Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J].
Hans, CP ;
Weisenburger, DD ;
Greiner, TC ;
Gascoyne, RD ;
Delabie, J ;
Ott, G ;
Müller-Hermelink, HK ;
Campo, E ;
Braziel, RM ;
Jaffe, ES ;
Pan, ZG ;
Farinha, P ;
Smith, LM ;
Falini, B ;
Banham, AH ;
Rosenwald, A ;
Staudt, LM ;
Connors, JM ;
Armitage, JO ;
Chan, WC .
BLOOD, 2004, 103 (01) :275-282
[9]   Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia [J].
Hillmen, Peter ;
Skotnicki, Aleksander B. ;
Robak, Tadeusz ;
Jaksic, Branimir ;
Dmoszynska, Anna ;
Wu, Jingyang ;
Sirard, Cynthia ;
Mayer, Jiri .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (35) :5616-5623
[10]   Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia [J].
Keating, MJ ;
O'Brien, S ;
Albitar, M ;
Lerner, S ;
Plunkett, W ;
Giles, F ;
Andreeff, M ;
Cortes, J ;
Faderl, S ;
Thomas, D ;
Koller, C ;
Wierda, W ;
Detry, MA ;
Lynn, A ;
Kantarjian, H .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4079-4088